<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-2448</journal-id>
<journal-title><![CDATA[Acta Medica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Med Colomb]]></abbrev-journal-title>
<issn>0120-2448</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-24482016000400229</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prueba de vasorreactividad con iloprost en hipertensión arterial pulmonar]]></article-title>
<article-title xml:lang="en"><![CDATA[Proof of vasoreactivity with iloprost in pulmonary arterial hypertension]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sénior]]></surname>
<given-names><![CDATA[Juan Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[Edison]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arévalo]]></surname>
<given-names><![CDATA[Edwin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tamayo]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia Cardiología Clínica e Intervencionista ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia Medicina Interna y Cardiología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Antioquia Medicina Interna y Cardiología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Antioquia Medicina Interna y Cardiología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad de Antioquia Medicina Interna y Cardiología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital Universitario San Vicente de Paúl Fundación Cardiología Intervencionista ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>41</volume>
<numero>4</numero>
<fpage>229</fpage>
<lpage>234</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-24482016000400229&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-24482016000400229&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-24482016000400229&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: la detección de vasorreactividad pulmonar en hipertensión pulmonar es importante para determinar el beneficio del tratamiento con calcioantagonistas a largo plazo. En los últimos años se ha utilizado el iloprost como alternativa para la realización de la prueba con buenos resultados, por lo que es importante evaluar su respuesta en pacientes con esta enfermedad.  Métodos: estudio cuasiexperimental no controlado con diseño de antes y después para evaluar la respuesta a un vasodilatador inhalado en pacientes remitidos al laboratorio de hemodinamia para pruebas de reactividad pulmonar. Se analizó una muestra no probabilística por conveniencia con la cohorte descrita. Se les realizó cateterismo derecho con medición de parámetros hemodinámicos y se evaluó la respuesta a la administración de 10 mcg de iloprost inhalado. Se consideró positiva la prueba si la presión arterial pulmonar media disminuía &gt; 10 mmHg hasta &lt; 40 mmHg, con aumento del gasto cardiaco o sin cambios en éste.  Resultados: se incluyeron 30 pacientes; el promedio de edad fue de 55.5 ± 12 años, el 76.7% fueron mujeres y la fracción de eyección del ventrículo izquierdo fue de 52 ± 10%. La prueba se consideró positiva en 16.7% de los casos, sin complicaciones relacionadas al uso del medicamento. Se observó aumento no significativo del gasto cardiaco, con descenso importante en la resistencia vascular sistémica (1279 ± 438 vs 1110± 379, p=0.000004), resistencia vascular pulmonar (483 ± 210 vs 383 ± 185, p=0.000002), presión arterial pulmonar (47 ± 6 vs 39 ± 7, p=0.000002) y presión en cuña de la arteria pulmonar (16 ± 5 vs 15 ± 4, p&lt;0.00009).  Conclusión: el uso de iloprost inhalado en dosis de 10 mcg, en pacientes con hipertensión pulmonar llevados a cateterismo cardiaco derecho es una alternativa para identificar vasorreactividad, con baja tasa de eventos adversos. (Acta Med Colomb 2016; 40: 229-234).]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: the detection of pulmonary vasoreactivity in pulmonary hypertension is important to determine the benefit of treatment with long-term calcium antagonists. In recent years, iloprost has been used as an alternative to perform the test with good results, so it is important to evaluate its response in patients with this disease.  Methods: a quasi-experimental, uncontrolled study with before and after design to evaluate the response to an inhaled vasodilator in patients referred to the hemodynamic laboratory for pulmonary reactivity tests. A non-probabilistic sample was analyzed for convenience with the described cohort. Right catheterization was performed with measurements of hemodynamic parameters and the response to administration of 10 mcg of inhaled iloprost was performed in these patients. The test was considered positive if mean pulmonary artery pressure decreased &gt;10 mmHg to &lt;40 mmHg, with or without cardiac output increase.  Results: 30 patients were included; mean age was 55.5 ± 12 years, 76.7% were women and the left ventricular ejection fraction was 52 ± 10%. The test was considered positive in 16.7% of cases, without complications related to the use of the drug. There was significant increase in cardiac output with an important decrease in systemic vascular resistance (1279 ± 438 vs 1110 ± 379, p = 0.000004), pulmonary vascular resistance (483 ± 210 vs 383 ± 185, p = 0.000002), blood pressure (47 ± 6 vs 39 ± 7, p = 0.000002), and wedge pressure of the pulmonary artery (16 ± 5 vs. 15 ± 4, p &lt;0.00009).  Conclusion: The use of inhaled iloprost in doses of 10 mcg in patients with pulmonary hypertension taken to right cardiac catheterization is an alternative to identify vasoreactivity with low rate of adverse events. (Acta Med Colomb 2016; 40: 229-234).]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[iloprost]]></kwd>
<kwd lng="es"><![CDATA[resistencia vascular]]></kwd>
<kwd lng="es"><![CDATA[hipertensión pulmonar]]></kwd>
<kwd lng="en"><![CDATA[iloprost]]></kwd>
<kwd lng="en"><![CDATA[vascular resistance]]></kwd>
<kwd lng="en"><![CDATA[pulmonary hypertension]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McLaughlin]]></surname>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary Hypertension]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zipes]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Libby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Braunwalds Heart Disease. A Textbook of Cardiovascular Medicine]]></source>
<year>2015</year>
<edition>10th</edition>
<page-range>1682-700</page-range><publisher-name><![CDATA[Elsevier Saunders Phil]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Bogaard]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Condliffe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Frantz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Definitions and diagnosis of pulmonary hypertension]]></article-title>
<collab>Kurzyna M et al</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>62</volume>
<numero>25 Suppl</numero>
<issue>25 Suppl</issue>
<page-range>D42-50</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frost]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Farber]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Barst]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Elliot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[McGoon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mmHg]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2013</year>
<volume>143</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>185-95</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGoon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gutterman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Steen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Barst]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McCrory]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fortin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Loyd]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening, early detection, and diagnosis of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2004</year>
<volume>126</volume>
<page-range>14S-34S</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tonelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alnuaimat]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mubarak]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary vasodilator testing and use of calcium cannel blockers in pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Resp Med]]></source>
<year>2010</year>
<volume>104</volume>
<page-range>481-96</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McLaughlin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2015</year>
<volume>65</volume>
<page-range>1976-97</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halliday]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hemnes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Robbins]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pugh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of acute vasodilator response in pulmonaiy arterial hypertension beyond the &#8220;classic&#8221; responders]]></article-title>
<collab>Piana R et al</collab>
<source><![CDATA[J Heart Lung Transp]]></source>
<year>2015</year>
<volume>34</volume>
<page-range>312-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galié]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Torbicki]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines on diagnosis and treatment of pulmonary hypertension The task force on diagnosis and treatment of pulmonary arterial hypertension of The European Society of Cardiology]]></article-title>
<collab>Barst R et al</collab>
<source><![CDATA[Eur Heart J]]></source>
<year>2004</year>
<volume>25</volume>
<page-range>2243-78</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sitbon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jais]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Ioos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hamid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension]]></article-title>
<collab>Provencher S et al</collab>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>111</volume>
<page-range>3105-11</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schrader]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Inbar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufmann]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vestal]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Rich]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the effects of adenosine and nifedipine in pulmonary hypertension]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1992</year>
<volume>19</volume>
<page-range>106-1064</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murali]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Uretsky]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation comparative effects of various pharmacologic agents]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1991</year>
<volume>122</volume>
<page-range>1375-81</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costard-Jackle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MB Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: Testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1992</year>
<volume>19</volume>
<page-range>48-54</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Givertz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hare]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Loh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gauthier]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Colucci]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction a rapid test for reversibility of pulmonary hypertrension]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1996</year>
<volume>28</volume>
<page-range>1775-80</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomberg-Maitland]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olschewski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostacyclin therapies for the treatment of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2008</year>
<volume>31</volume>
<page-range>891-901</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<collab>Olschewski H1.Ghofrani HA.Walmrath D.Schermuly R.Temmesfeld-Wollbruck B.Grimminger F.Seeger W</collab>
<article-title xml:lang=""><![CDATA[Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1999</year>
<volume>160</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>600-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[ZC]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[ZY]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[XQ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension]]></article-title>
<collab>Wu Y et al</collab>
<source><![CDATA[Eur Respir J]]></source>
<year>2009</year>
<volume>33</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1354-60</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Opitz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wensel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bettman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schaffarczyk]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Linscheid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hetzer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ewert]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing of the vasodilator response in primary pulmonary hypertension]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2003</year>
<volume>24</volume>
<page-range>356-65</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caojin]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yigao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wenhui]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chunli]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xinsheng]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of acute hemodynamic effects of aerosolized iloprost and inhaled nitric oxide in adutl congenital heart disease with severe pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Intern Med]]></source>
<year>2012</year>
<volume>51</volume>
<page-range>2857-62</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rimensberger]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Spahr-Schopfer]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Berner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jaeggi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kalangos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Friedli]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Beghetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2001</year>
<volume>103</volume>
<page-range>544-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olschewski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ghofrani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkens]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Winkler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension]]></article-title>
<collab>Borst M et al</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2000</year>
<volume>35</volume>
<page-range>176-82</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Meng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sheng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension]]></article-title>
<collab>Han X et al</collab>
<source><![CDATA[Int J Cardiol]]></source>
<year>2011</year>
<volume>147</volume>
<page-range>433-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Opitz]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Blindt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Blumberg]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Borst]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Bruch]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary hypertension Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011]]></article-title>
<collab>Leuchte HH et al</collab>
<source><![CDATA[Int J Cardiol]]></source>
<year>2011</year>
<volume>154</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S13-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moscucci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood flow measurement: cardiac output and vascular resistance]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Moscucci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Grossman &amp; Baim's Cardiac Catheterization, Angiography, and Intervention]]></source>
<year>2014</year>
<edition>8th</edition>
<page-range>245-60</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Wolters Kluwer/Lippincott Williams and Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Barbera]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis, assessment, and treatment of nonpulmonary arterial hypertension pulmonary hypertension]]></article-title>
<collab>Channick RN Hassoun PM.Lang IM.Manes A et al</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2009</year>
<volume>54</volume>
<page-range>S85-96</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McLaughlin]]></surname>
<given-names><![CDATA[VV]]></given-names>
</name>
<name>
<surname><![CDATA[McGoon]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2006</year>
<volume>114</volume>
<page-range>1417-31</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xiong]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Ni]]></surname>
<given-names><![CDATA[XH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute responses to inhalation of Iloprost in patients with pulmonary hypertension]]></article-title>
<collab>He JG et al</collab>
<source><![CDATA[Chin Med J]]></source>
<year>2012</year>
<volume>125</volume>
<page-range>2826-31</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Voswinckel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Palazzini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jais]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complications of right catheterization procedures in patients with pulmonary hypertension in experienced centers]]></article-title>
<collab>Marinelli A et al</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2006</year>
<volume>48</volume>
<page-range>2546-52</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galiè]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vachiery]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbs]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Torbicki]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2015</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
